As expected, tamatinib as well as entospletinib effectively blocked the phosphorylation of SYK, and its downstream components STAT3 and AKT in MYD88 only mutated WM cells, as well as in ABC DLBCL cell lines carrying both MYD88 and CD79B activating mutations (Fig. 4b). The gene discussed is AKT1; the disease is diffuse large B-cell lymphoma.